Loading...

APC anti-mouse CD3ε Antibody APC anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_APC_021606
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
  • 145-2C11_APC_021606
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100311 25 µg DKK197
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100312 100 µg DKK624
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  2. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  3. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  4. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  5. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  6. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  7. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  8. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  9. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  10. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  11. Nelson J, et al. 2020. Sci Adv. 6:eaaz6893. PubMed
  12. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  13. Wang B, et al. 2022. EMBO J. 41:e108946. PubMed
  14. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  15. Cha JH, et al. 2022. J Biol Chem. 298:101817. PubMed
  16. Khayrullina G, et al. 2022. Glia. 70:1337. PubMed
  17. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  18. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  19. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  20. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  21. Agrafiotis A, et al. 2023. Acta Neuropathol. 145:335. PubMed
  22. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  23. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  24. Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed
  25. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  26. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  27. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  28. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  29. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  30. Fujimori S, et al. 2022. Elife. 11:. PubMed
  31. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  32. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  33. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  34. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  35. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  36. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  37. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  38. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  39. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  40. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  41. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  42. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  43. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  44. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  45. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  46. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  47. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  48. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  49. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  50. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  51. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  52. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  53. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  54. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  55. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  56. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  57. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  58. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  59. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  60. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  61. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  62. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  63. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  64. Dong S, et al. 2021. Nature. 591:117. PubMed
  65. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  66. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  67. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  68. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  69. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  70. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  71. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  72. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  73. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  74. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  75. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  76. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  77. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  78. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  79. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  80. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  81. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  82. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  83. XS R, et al. 2015. Diabetes. 64 90. PubMed
  84. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  85. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  86. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  87. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  88. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  89. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  90. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  91. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  92. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  93. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  94. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  95. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  96. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  97. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  98. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  99. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  100. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  101. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  102. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  103. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  104. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  105. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  106. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  107. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  108. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  109. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  110. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  111. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  112. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  113. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  114. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  115. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  116. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  117. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  118. Koide S, et al. 2022. iScience. 25:103603. PubMed
  119. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  120. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  121. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  122. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  123. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  124. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  125. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  126. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  127. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  128. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  129. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  130. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  131. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  132. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  133. Huang X, et al. 2021. Immunity. . PubMed
  134. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  135. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  136. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  137. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  138. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  139. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  140. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  141. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  142. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  143. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  144. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  145. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  146. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  147. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  148. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  149. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  150. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  151. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  152. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  153. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  154. Nelson J, et al. 2020. Sci Adv. 6:eaaz6893. PubMed
  155. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  156. Wang B, et al. 2022. EMBO J. 41:e108946. PubMed
  157. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  158. Cha JH, et al. 2022. J Biol Chem. 298:101817. PubMed
  159. Khayrullina G, et al. 2022. Glia. 70:1337. PubMed
  160. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  161. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  162. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  163. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  164. Agrafiotis A, et al. 2023. Acta Neuropathol. 145:335. PubMed
  165. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  166. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  167. Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed
  168. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  169. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  170. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  171. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  172. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  173. Fujimori S, et al. 2022. Elife. 11:. PubMed
  174. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  175. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  176. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  177. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  178. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  179. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  180. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  181. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  182. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  183. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  184. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  185. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  186. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  187. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  188. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  189. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  190. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  191. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  192. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  193. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  194. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  195. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  196. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  197. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  198. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  199. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  200. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  201. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  202. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  203. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  204. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  205. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  206. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  207. Dong S, et al. 2021. Nature. 591:117. PubMed
  208. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  209. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  210. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  211. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  212. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  213. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  214. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  215. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  216. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  217. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  218. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  219. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  220. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  221. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  222. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  223. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  224. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  225. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  226. XS R, et al. 2015. Diabetes. 64 90. PubMed
  227. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  228. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  229. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  230. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  231. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  232. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  233. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  234. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  235. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  236. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  237. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  238. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  239. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  240. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  241. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  242. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  243. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  244. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  245. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  246. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  247. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  248. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  249. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  250. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  251. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  252. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  253. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  254. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  255. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  256. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  257. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  258. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  259. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  260. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  261. Koide S, et al. 2022. iScience. 25:103603. PubMed
  262. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  263. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  264. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  265. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  266. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  267. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  268. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  269. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  270. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  271. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  272. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  273. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  274. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  275. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  276. Huang X, et al. 2021. Immunity. . PubMed
  277. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  278. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  279. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  280. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  281. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  282. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  283. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  284. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  285. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  286. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
RRID
AB_312676 (BioLegend Cat. No. 100311)
AB_312677 (BioLegend Cat. No. 100312)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_APC_021606
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
  • 145-2C11_APC_021606
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100311 25 µg DKK197
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100312 100 µg DKK624
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  2. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  3. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  4. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  5. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  6. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  7. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  8. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  9. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  10. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  11. Nelson J, et al. 2020. Sci Adv. 6:eaaz6893. PubMed
  12. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  13. Wang B, et al. 2022. EMBO J. 41:e108946. PubMed
  14. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  15. Cha JH, et al. 2022. J Biol Chem. 298:101817. PubMed
  16. Khayrullina G, et al. 2022. Glia. 70:1337. PubMed
  17. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  18. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  19. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  20. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  21. Agrafiotis A, et al. 2023. Acta Neuropathol. 145:335. PubMed
  22. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  23. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  24. Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed
  25. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  26. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  27. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  28. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  29. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  30. Fujimori S, et al. 2022. Elife. 11:. PubMed
  31. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  32. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  33. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  34. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  35. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  36. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  37. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  38. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  39. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  40. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  41. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  42. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  43. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  44. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  45. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  46. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  47. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  48. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  49. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  50. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  51. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  52. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  53. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  54. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  55. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  56. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  57. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  58. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  59. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  60. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  61. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  62. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  63. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  64. Dong S, et al. 2021. Nature. 591:117. PubMed
  65. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  66. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  67. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  68. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  69. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  70. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  71. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  72. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  73. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  74. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  75. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  76. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  77. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  78. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  79. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  80. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  81. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  82. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  83. XS R, et al. 2015. Diabetes. 64 90. PubMed
  84. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  85. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  86. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  87. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  88. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  89. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  90. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  91. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  92. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  93. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  94. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  95. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  96. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  97. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  98. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  99. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  100. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  101. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  102. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  103. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  104. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  105. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  106. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  107. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  108. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  109. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  110. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  111. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  112. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  113. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  114. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  115. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  116. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  117. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  118. Koide S, et al. 2022. iScience. 25:103603. PubMed
  119. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  120. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  121. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  122. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  123. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  124. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  125. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  126. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  127. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  128. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  129. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  130. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  131. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  132. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  133. Huang X, et al. 2021. Immunity. . PubMed
  134. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  135. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  136. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  137. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  138. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  139. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  140. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  141. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  142. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  143. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  144. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  145. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  146. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  147. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  148. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  149. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  150. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  151. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  152. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  153. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  154. Nelson J, et al. 2020. Sci Adv. 6:eaaz6893. PubMed
  155. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  156. Wang B, et al. 2022. EMBO J. 41:e108946. PubMed
  157. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  158. Cha JH, et al. 2022. J Biol Chem. 298:101817. PubMed
  159. Khayrullina G, et al. 2022. Glia. 70:1337. PubMed
  160. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  161. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  162. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  163. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  164. Agrafiotis A, et al. 2023. Acta Neuropathol. 145:335. PubMed
  165. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  166. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  167. Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed
  168. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  169. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  170. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  171. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  172. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  173. Fujimori S, et al. 2022. Elife. 11:. PubMed
  174. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  175. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  176. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  177. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  178. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  179. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  180. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  181. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  182. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  183. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  184. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  185. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  186. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  187. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  188. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  189. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  190. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  191. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  192. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  193. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  194. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  195. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  196. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  197. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  198. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  199. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  200. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  201. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  202. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  203. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  204. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  205. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  206. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  207. Dong S, et al. 2021. Nature. 591:117. PubMed
  208. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  209. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  210. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  211. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  212. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  213. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  214. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  215. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  216. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  217. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  218. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  219. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  220. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  221. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  222. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  223. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  224. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  225. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  226. XS R, et al. 2015. Diabetes. 64 90. PubMed
  227. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  228. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  229. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  230. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  231. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  232. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  233. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  234. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  235. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  236. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  237. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  238. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  239. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  240. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  241. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  242. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  243. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  244. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  245. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  246. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  247. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  248. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  249. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  250. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  251. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  252. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  253. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  254. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  255. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  256. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  257. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  258. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  259. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  260. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  261. Koide S, et al. 2022. iScience. 25:103603. PubMed
  262. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  263. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  264. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  265. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  266. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  267. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  268. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  269. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  270. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  271. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  272. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  273. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  274. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  275. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  276. Huang X, et al. 2021. Immunity. . PubMed
  277. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  278. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  279. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  280. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  281. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  282. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  283. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  284. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  285. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  286. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
RRID
AB_312676 (BioLegend Cat. No. 100311)
AB_312677 (BioLegend Cat. No. 100312)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account